What this is
- How it works
- How it works isn't classified yet
- Tested for
- Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy
- Main trialPhase 1
- “This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor”In the company’s words, NCT07584954 on ClinicalTrials.gov
Other drugs for Solid Tumor Cancer
- BCD-217Biocad · Phase 3
- ProlgolimabBiocad · Phase 3
- BalstilimabAgenus Inc. · Phase 2
- BotensilimabAgenus Inc. · Phase 2
- SYS6088CSPC · Phase 1/2
- GB268Eddingpharm (Zhuhai) Co., Ltd. · Phase 1/2
Coming up1
- 30 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Jun 2028 | Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026